The FDA is seeking public feedback on how to regulate generative AI in medical devices, recognizing both its promise and risks.
Key Details
- 1FDA has released a discussion paper on regulatory approaches for generative AI in medical devices.
- 2The agency is focusing on risk assessment, premarket evaluation, and postmarket safety monitoring.
- 3Radiologist Rick Abramson, MD, now heads the FDA Digital Health Center and emphasizes the need for leadership in this area.
- 4Comments are invited from stakeholders including physicians, device makers, and researchers until October 19.
- 5The FDA aims for a nimble, risk-based, and minimally burdensome regulatory approach.
Why It Matters
This marks a significant step toward shaping how generative AI, including in radiology, will be safely and efficiently integrated into medical practice. Stakeholder engagement now is likely to influence future regulatory pathways for advanced imaging AI tools.
Source
Radiology Business
Related News
•Radiology Business
Radiology Partners Urges FDA for Clarity on Imaging AI Regulations
Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.
•HealthExec
AI's Role in Eliminating Cervical Cancer: A Model for Disease Prevention
Researchers highlight how AI can accelerate the elimination of cervical cancer and set a precedent for combating other diseases.
•Radiology Business
ABR Sets Guardrails for AI Use in Radiologist Certification
The American Board of Radiology is taking a cautious, structured approach to integrating AI into its certification processes.